Practical Strategies to a successful 505(b)(2) product

Website http://www.onlinecompliancepanel.com?expDate=Ourglocal | Edit Freely

Category 508 compliance; act compliance; fda compliance; ada compliance; advisor compliance; argent software pci compliance; certificate of compliance; code compliance; compliance; compliance audit; compliance checklist; compliance issues; compliance jobs; compliance management; compliance manager; compliance manual; compliance monitoring; compliance monitoring ppt; compliance officer; compliance plan; compliance plans; compliance program; compliance software; compliance solutions; compliance testing; compliance training; compliance with; contract compliance; corporate compliance; email compliance; environmental compliance; export compliance; health care compliance; healthcare compliance; hipaa compliance; hippa compliance; investment advisor compliance; medical compliance; medication compliance; non compliance; osha compliance; osha compliance training; pci compliance; policy compliance; regulatory compliance; rohs compliance; safety compliance; sarbanes oxley compliance; security compliance; sox compliance; tax comp

Deadline: May 24, 2014 | Date: May 24, 2014

Venue/Country: 38868 Salmon Ter, Fremont, U.S.A

Updated: 2014-04-17 18:00:38 (GMT+9)

Call For Papers - CFP

Description:

A 505(b)(2) product is an improved or altered version or a new use application for a previously FDA-approved drug. This unique regulatory pathway, available only for marketing approval in the US, offers an attractive pathway to cheaper and faster new drug development, particularly to a manufacturer with experience in developing generic products. It involves making significant changes to an existing FDA approved product, called reference product, to create a new product with its own indication, formulation, population, and/or other differences that need to be supported with clinical studies. A major advantage of this pathway is that it allows a sponsor to rely, at least in part, on the FDA's findings of safety and/or effectiveness for a previously approved drug, thereby reducing the number of clinical trials required for approval. The biggest incentive to develop 505(b)(2) products is 3 years of market exclusivity available to the approved product.

Why Should you Attend:

Despite being around for more than 25 years, same as generic drugs, the 505(b)(2) products have only recently become more popular. The main reason is that due to several similarities with generic products, 505(b)(2) products offer some unique challenges. Just like NDAs for new drugs, 505(b)(2) products are subject to full user fee under the Prescription Drug User Fee Act (PDUFA), could require several clinical and non-clinical studies and could take a significant allocation of resources, albeit less than that for a brand new product but much higher than that for a generic drug. Like all drug development strategies, 505(b)(2) pathway requires careful consideration and planning taking into account all the potential issues to be addressed before embarking on development. These issues include intellectual property concerns, supporting information available either from reference products or literature, the logistics of conducting clinical trials with generic-like products, market competition for approved products and business considerations for international product launch.

Every year FDA approves about twice the number of 505(b)(2) applications compared to traditional 505(b)(1) applications. It is projected that due to increased challenges in creating new products, 505(b)(2) products might comprise more than 70% of all FDA approvals over the next 10 years. This pathway is particularly attractive to manufacturers transitioning from generic drugs to innovator products. Due to the similarities with traditional drug development, they offer a low risk market entry point by training the work force in the traditional development processes. However, as would be evident, there are unique challenges to developing such products ? scientific, regulatory, logistical and financial ? all of which could convert a potentially attractive project into a constant headache.

This seminar will discuss the practical strategies for drug development via 505(b)(2) regulatory pathway. Key strategic considerations will be discussed using real-life case studies. Also discussed will be role of interactions with the FDA, global clinical trials, market access, reimbursement issues and projected trends for the near future. Lastly, the 505(b)(2) pathway will be compared to that for biosimilars.

Learning Objectives:

Know the complete details, key strategies, regulatory considerations, and marketing strategies for developing 505(b)(2) products.

Objectives of the Presentation:

The 505(B)(2) regulation and guidance from the FDA

Strategic considerations before embarking on a 505(b)(2) development project

Intellectual property issues with such products

Key development steps for such products

FDA's review process and ongoing consultation

Challenges to developing 505(b)(2) product and possible solutions

Examples of successful strategies for developing such products

Searching for a 505(b)(2) project, future trends

505(b)(2) and biosimilars

Who can Benefit:

This webinar will provide valuable assistance to all personnel in:

Regulatory Affairs Professionals

Senior Management Executives (CEO, COO, CFO, etc)

Drug discovery and development professionals (R&D and CMC)

Intellectual Property Experts

Project Managers and Clinical trial specialists

Regulatory Compliance Associates and Managers

People investing in FDA-regulated product development projects

http://www.onlinecompliancepanel.com/ecommerce/webinar/~product_id=500293?expDate=Ourglocal